European Foundation for the Study of Diabetes
European Foundation for the Study of Diabetes (EFSD) and Sanofi
European Diabetes Research Programme in Macrovascular Complications
Request for Applications
Deadline for submission of applications: 15 March 2017
The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide multiple funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi Diabetes and Cardiovascular is dedicated to delivering innovative, value-based medicines and integrated solutions. Sanofi is committed to a collaborative approach that involves strategic alliances with professional and patient associations, research institutions and leaders in healthcare and other industries, with the goal of advancing scientific knowledge, driving the convergence of science and technology, helping to improve outcomes and inspiring and evolution in care.
Programme Research and Focus
EFSD and Sanofi have established a new programme called the EFSD/Sanofi European Diabetes Research Programme in Macrovascular Complications to encourage new projects aimed at advancing current knowledge in this field. To achieve the goals and objectives of this Programme, EFSD and Sanofi invite applications by issuring this "Request for Applications" (RFA) which indicates joint funding as well as areas of research emphasis. The EFSD/Sanofi European Diabetes Research Programme is intended to stimulate and accelerate European research on macrovascular complications. Grants are offered for basic or clinical mechanistic studies. For the former, innovative studies including use of advance stem cell approaches will be particularly welcome, whereas studies involving classical animal models of macrovascular disease will not be considered for funding.